CaviCide and CaviWipes Efficacy Regarding Coronavirus
CaviCide, which is the solution used to impregnate CaviWipes, has an EPA-registered label claim against Human Coronavirus.
Metrex has recently performed an efficacy study on CaviWipes against the SARS-CoV (SARS-associated Human Coronavirus) in a third-party test lab. According to the study report, the study results passed the Viricidal Hard Surface Efficacy Test by exceeding a 3-log/ 99.9% reduction of the virus. However, this study result has not yet been reviewed or approved by the US EPA. CaviWipes does not have an Emerging Viral Pathogen claim, nor a labelling claim against Human Coronavirus.
Even though SARS-CoV, Human Coronavirus, and SARS-COV-2 are not the same virus strains, all coronavirus strains are enveloped viral particles that belong to the same virus family of Coronaviridae. Enveloped viral particles are typically more susceptible to chemical disinfectant formulations than are other common pathogens2.
- Interim Infection Prevention and Control Recommendations for Patients with Confirmed Coronavirus Disease 2019 (COVID-19) or Persons Under Investigation for COVID-19 in Healthcare Settings. https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Finfection-control.html. Accessed 3.3.2020.
- Sattar, S. “Hierarchy of Susceptibility of Viruses to Environmental Surface Disinfectants: A Predictor of Activity Against new and Emerging Viral Pathogens”. Journal of AOAC International. 2007. Vol 90.6. https://www.researchgate.net/publication/5657319_Hierarchy_of_Susceptibility_of_Viruses_to_Environmental_Surface_Disinfectants_A_Predictor_of_Activity_Against_New_and_Emerging_Viral_Pathogens. Accessed